Industry Weighs in on CIPA, PAH and More
Getting out of the lab and networking with colleagues to check the pulse of the industry is central to our resource and development planning.
The CorDynamics team returned last month from a very productive Safety Pharmacology Society exhibition in Prague, Czech Republic. The mood was very upbeat, with many clients and friends expressing satisfaction with the positive state of our industry. We’ve always enjoyed the rotating geographic nature of this particular meeting – splitting time biennially between Europe and North America. This year, we appreciated that many of the over 450 attendees stopped by our booth to catch up and discuss the current state of the pharma industry.
As expected, many safety pharmacology issues were discussed and several included topics we’ve seen before.
Safety Pharmacology Hot Topics Heading Into 2016
Comprehensive In Vitro Pro-Arrhythmia Assay (CIPA)
While it remains to be seen exactly what the final scheme will look like, it’s clear the comprehensive in vitro proarrhythmia paradigm will continue to hold the torch as a leading area for discussion – and spirited debate – for the foreseeable future. We agree with a number of colleagues who purported the benefits of a complete preclinical integrated cardiovascular risk assessment vis-a-vis decision making. (Learn more about integrated risk assessments alongside CIPA.)
Integrative Pharmacology and Translation to the Clinic
The focus on integrative pharmacology with an eye toward the clinic is a welcomed and embraced narrative. The SPS agenda included cardiovascular symposia on drug interactions with baroreceptor function, models in anti-diabetics, along with a clinical perspective on severe cardiopulmonary disease. We presented some very recent data on the interventional use of both Riociguat and sildenafil against established PAH in the hypoxia/VEGF antagonist model.